Ceribell CBLL 深 滬
已收盤 08-01 16:00:00 美东时间
14.14
-0.260
-1.81%
華盛通- 最 高14.41
- 今 開14.35
- 成交量 27.28万股
- 最 低 14.09
- 昨 收 14.40
- 總市值 5.11亿
- 52周最高 32.7489
- 市盈率 靜 --
- 換手率 0.75%
- 52周最低 10.01
- 委 比 42.11%
- 總股本 3614.30万
- 歷史最高 32.7489
- 量 比 1.24
- 振 幅 2.22%
- 歷史最低 10.01
- 每 手 1
- 風險率 3.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference
Ceribell, Inc. (Nasdaq: CBLL) announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. PST / 2:00 p.m. EST. A live and archived webcast will be available on the company's Investor Relations website. Ceribell, a medical technology company, focuses on advancing neurological patient care through its FDA-cleared Ceribell System, which aids in rapid diagn...
07-29 20:05
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
Ceribell, Inc. announced the release of its second-quarter 2025 financial results on August 5, 2025, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET same day to discuss results. A live and archived webcast is available on the company's investor relations page. Ceribell focuses on transforming neurological patient care and markets the FDA-cleared Ceribell System, used in U.S. ICUs and ERs. Headquartered in...
07-22 20:05
Ceribell sues Natus Medical for patent infringement
CeriBell (NASDAQ:CBLL) said on Monday that it has taken legal action against Natus Medical and its units, claiming that they have infringed on its patents and engaged in unfair competition. Ceribell h...
07-08 05:06
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Ceribell, Inc. filed patent infringement lawsuits against Natus Medical Incorporated and its subsidiaries, alleging violations related to its EEG headband and electrode design technology. Ceribell requested the U.S. International Trade Commission (USITC) to investigate and issue an exclusion order to block Natus' infringing products from entering the U.S. Additionally, Ceribell filed a complaint with the U.S. District Court in Delaware. The compa...
07-07 20:42
Ceribell Extends Exclusive License with Stanford University
An announcement from Ceribell, Inc. ( ($CBLL) ) is now available. Ceribell, Inc...
06-21 01:18
AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- Equity Insider News Commentary – Amid the wave of new AI-powered innov...
06-20 21:11
CeriBell Raises FY2025 Sales Guidance from $81.00M-$85.00M to $83.00M-$87.00M vs $83.72M Est
CeriBell (NASDAQ:CBLL) raises FY2025 sales outlook from $81.00 million-$85.00 million to $83.00 million-$87.00 million vs $83.72 million estimate.
05-09 06:54
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE:SRE) is likely to report qua...
05-08 16:33
美股大行评级 | 潜在涨幅1543.84%！Compass Therapeutics获HC Wainwright升目标价至24美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1115197988923084800.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Compass Therapeutics(CMPX)"买入"评级，目标价从10美元升至24美元</p> <p>• 瑞杰金融：维持Freeport-McMoRan(FCX)
04-07 10:45
美股大行评级 | Susquehanna：维持AerCap Holdings"积极"评级，目标价从108美元升至120美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1102154574572916737.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Prothena Corp(PRTA)"超配"评级，目标价从94美元升至110美元</p> <p>• Stifel：维持GH Research(GHRS)"买入"评级，目标价从18美元升至3
02-28 09:50
